Organization
The Sarah Cannon Research Institute
4 abstracts
Abstract
A phase 1/2 study of the safety, tolerability, and preliminary efficacy of the anti-GITR monoclonal antibody, INCAGN01876, combined with immunotherapies (IO) in patients (Pts) with advanced cancers.Org: Hackensack University Medical Center, The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, Karmanos Cancer Institute, The Sarah Cannon Research Institute, Stephenson Cancer Center,
Abstract
A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, The Sarah Cannon Research Institute, Division of Hematology/Oncology, Henry Ford Health System, Pfizer, Inc.,
Abstract
A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors.Org: City of Hope Comprehensive Cancer Center, University of Texas MD Anderson Cancer Center, The Sarah Cannon Research Institute, Knight Cancer Institute, Cedars-Sinai Cancer Center,
Abstract
Phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate (ADC) MYTX-011 in subjects with non-small cell lung cancer.Org: NEXT Oncology - Virginia Cancer Specialists, The Sarah Cannon Research Institute, Department of Thoracic Medical Oncology, The University of Texas MD Anderson Cancer Center, UPMC Hillman Cancer Center, Medical College of Wisconsin,